Although iron dextran has historically correlated with significant rates of adverse drug events, a retrospective review by Chertow et al. demonstrated that the majority of reported events were from the use of high-molecular-weight formulations of iron dextran, which are no longer available on the market.

Intramuscular infusions may additionally be associated with gluteal sarcomas and the following at the injection site: cellulitis, fibrosis, phlebitis, permanent skin discoloration, and localized myalgia.